



# Comparison of Acute COVID-19 Encephalopathy with Seasonal Influenza A-Associated Encephalopathy

Jialu Xu<sup>1</sup>, Wei Li<sup>2</sup>, Yilin Zhu<sup>3</sup>, Jiajin Wang<sup>4</sup>, Haifeng Li<sup>1,\*</sup>

<sup>1</sup> Department of Rehabilitation, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China

<sup>2</sup> Department of Clinical Laboratory, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China

<sup>3</sup> Department of Pediatrics, the First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

<sup>4</sup> Department of Neonate, Shaoxing Keqiao Women & Children's Hospital, Shaoxing, China

\* Corresponding author: Department of Rehabilitation, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China. Email: 6199005@zju.edu.cn

Received 2023 November 12; Revised 2024 March 2; Accepted 2024 March 28.

## Abstract

**Objectives:** To compare the clinical presentations and neurobiological features in children with acute Coronavirus disease 2019 (COVID-19) encephalopathy and Seasonal influenza A virus (IAV)-associated encephalopathy.

**Methods:** We conducted a retrospective cohort study on patients diagnosed with COVID-19 encephalopathy between December 15, 2022, and January 15, 2023, and children diagnosed with IAV-associated encephalopathy between November 2017 and March 2023, who were less than 18 years old at the Children's Hospital, Zhejiang University School of Medicine.

**Results:** A total of 34 patients with acute COVID-19 encephalopathy and 37 patients with IAV-associated encephalopathy were included in this study. Elevation of cerebrospinal fluid (CSF) pleocytosis and CSF glucose, as well as downregulation of monocyte and TNF- $\alpha$ , were observed in both the COVID-19 ICU group and the moderate & severe group. The median age was younger ( $P < 0.001$ ) and the median time for the occurrence of neurological symptoms was shorter ( $P < 0.001$ ) in the COVID-19 group compared with the IAV group. More patients in the IAV group had altered levels of consciousness ( $P < 0.001$ ) and were admitted to the ICU ( $P < 0.001$ ). Consequently, more severe cases were observed in the IAV group ( $P = 0.007$ ). Brain imaging showed a predominance appearance of acute necrotizing encephalopathy in the IAV group ( $P = 0.038$ ). Regarding blood parameters, leukomonocyte levels were lower in the IAV group ( $P = 0.003$ ) with lower expression of CD4 ( $P = 0.047$ ). Random blood glucose ( $P = 0.001$ ), D dimer ( $P = 0.004$ ), and cytokine IL-2 ( $P = 0.005$ ) were lower in the COVID-19 group, while IFN- $\gamma$  ( $P = 0.013$ ) was significantly higher.

**Conclusions:** Influenza A virus-associated encephalopathy presented more severe manifestations. However, IFN- $\gamma$  may act as a protective cytokine in COVID-19 encephalopathy.

**Keywords:** COVID-19 Encephalopathy, Seasonal Influenza A-Associated Encephalopathy, Acute Necrotizing Encephalopathy, IFN- $\gamma$

## 1. Background

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). While COVID-19 is generally considered a mild disease in most pediatric patients (1, 2), it can lead to various degrees of neurological sequelae affecting the central or peripheral nervous system (3). With the increasing spread of the virus, there has been a rise in the prevalence of acute encephalopathy, known as COVID-19 encephalopathy (4, 5), even in infants and

toddlers (6). Additionally, acute encephalopathy is a common neurological symptom of seasonal influenza A (7), particularly affecting young children (8). Acute necrotizing encephalopathy (ANE), the most severe form of acute encephalopathy characterized by necrosis of the deep gray matter of the brain, can be induced by both COVID-19 and influenza (9, 10).

## 2. Objectives

In this article, we conducted a retrospective cohort study comparing acute COVID-19 encephalopathy with

influenza A virus (IAV)-associated encephalopathy in children.

### 3. Methods

#### 3.1. Study Population

This retrospective cohort study included children diagnosed with laboratory-confirmed COVID-19 between December 15, 2022, and January 15, 2023, and children diagnosed with seasonal influenza A between November 2017 and March 2023, who were under 18 years old at the Children's Hospital, Zhejiang University School of Medicine. The study was approved by the ethics committee of Children's Hospital, Zhejiang University School of Medicine (2019-IRB-091).

#### 3.2. Diagnostic Criteria

Coronavirus disease 2019 or IAV infection was defined by a positive viral antigen test and/or viral RNA detection using a nasopharyngeal aspirate or throat swab. Patients with encephalopathy were identified based on clinical symptoms and signs consistent with acute encephalitis/encephalopathy, characterized by a febrile disorder accompanied by altered consciousness and slow activity on electroencephalography lasting for more than 24 hours after an acute onset, with no evidence of bacteria or fungi on cerebrospinal fluid (CSF) culture. All other neurological, vascular, metabolic, endocrine, toxic, and drug-induced disorders were excluded (11, 12). Acute necrotizing encephalopathy was defined by the presence of multiple, symmetrical lesions in the thalami, putamina, cerebral and cerebellar white matter, and brainstem (13). Status epilepticus (SE) was defined as continuous seizure activity lasting longer than 5 minutes or recurrent seizures without regaining consciousness between seizures for more than 5 minutes (14). The severity of COVID-19 or IAV infection was categorized as follows: Mild cases referred to children who did not require oxygen supplementation, moderate cases required oxygen supplementation, and severe cases required noninvasive or invasive mechanical ventilation (15).

#### 3.3. Data Collection

The following information was collected for statistical analysis: Demographics (age, sex), neurological symptoms at presentation, blood parameters (routine, biochemical, C-reactive protein (CRP), procalcitonin (PCT), erythrocyte sedimentation rate (ESR), cytokines, etiology, and culture), CSF profile

(routine, biochemical, etiology, and culture), electroencephalogram (EEG) findings, and neuroimaging results. Abnormal brain imaging findings were defined as hypointensity on magnetic resonance imaging (MRI) T1-weighted images (T1WI) and hyperintensity on T2-weighted images (T2WI) and fluid-attenuated inversion recovery (FLAIR), or hypodensity on computed tomography (CT) scans. The EEG findings were categorized as follows: (1) normal, (2) diffuse or focal slow waves, and (3) epileptiform activity.

#### 3.4. Statistical Analysis

The data were analyzed using SPSS 27.0 statistical software and presented as the median for non-normally distributed variables. Non-parametric tests or the Kruskal-Wallis test were employed for continuous variables, while chi-square with Bonferroni correction or Fisher's exact test was used for categorical variables. A P-value of less than 0.05 ( $P < 0.05$ ) was considered statistically significant.

## 4. Results

#### 4.1. Characteristics of the COVID-19 Encephalopathy Group

This study included a total of 34 patients with acute COVID-19 encephalopathy. The COVID-19 group was divided into ICU and non-ICU groups, as well as mild and moderate and severe groups, separately. In the ICU group, 83.3% of patients exhibited altered levels of consciousness ( $P < 0.001$ ), accompanied by elevated CSF pleocytosis ( $P = 0.046$ ), CSF glucose ( $P = 0.007$ ), and PCT ( $P = 0.046$ ), along with downregulation of peripheral blood monocytes ( $P = 0.003$ ) and TNF- $\alpha$  ( $P = 0.01$ ) (Table 1). Meanwhile, in the moderate & severe COVID-19 group, 71.4% of patients had altered levels of consciousness ( $P < 0.001$ ), with elevated CSF pleocytosis ( $p = 0.046$ ) and CSF glucose ( $P = 0.007$ ), alongside downregulation of peripheral blood leukomonocytes ( $P = 0.018$ ), monocytes ( $P = 0.016$ ), and TNF- $\alpha$  ( $P = 0.01$ ) (Table 2).

#### 4.2. Characteristics of the Influenza A Virus (IAV) Encephalopathy Group

This study included a total of 37 patients diagnosed with IAV-associated encephalopathy. We conducted separate comparisons between the ICU and non-ICU groups, as well as between the mild and the moderate & severe groups within the IAV cohort. The ICU group exhibited a longer duration before the onset of neurological symptoms ( $P = 0.019$ ), a higher incidence

**Table 1.** Comparison of COVID-19 Encephalopathy ICU Group with Non-ICU Group

COVID-19 Severity	ICU (n = 6)	Non-ICU (n = 28)	P-Value
ALOC; No. (%)	5 (83.3)	0 (0)	< 0.001
CSF pleocytosis, 10 <sup>6</sup> /L	3 (2 - 5.5)	1 (1 - 2)	0.046
CSF glucose, mmol/L	5.79 (4.90 - 6.12)	3.96 (3.30 - 4.53)	0.007
PCT, ng/mL	0.55 (0.38 - 36.18)	0.33 (0.12 - 0.61)	0.046
Monocyte, 10 <sup>9</sup> /L	0.23 (0.22 - 0.41)	0.61 (0.43 - 0.89)	0.003
TNF-α, pg/mL	1.10 (1.00 - 1.23)	2.60 (1.15 - 3.10)	0.01

**Table 2.** Comparison of COVID-19 Encephalopathy Mild Group with Moderate and Severe Group

COVID-19 Severity	Mild (n = 27)	Moderate and Severe (n = 7)	P-Value
ALOC; No. (%)	0 (0)	5 (71.4)	< 0.001
CSF pleocytosis, 10 <sup>6</sup> /L	1 (1 - 2)	3 (2 - 5.5)	0.046
CSF glucose, mmol/L	3.96 (3.30 - 4.53)	5.79 (4.90 - 6.12)	0.007
Leukomonocyte, 10 <sup>9</sup> /L	3.00 (1.77 - 4.23)	1.07 (0.66 - 2.16)	0.018
Monocyte, 10 <sup>9</sup> /L	0.61 (0.42 - 0.90)	0.23 (0.22 - 0.45)	0.016
TNF-α, pg/mL	2.65 (1.18 - 3.20)	1.20 (1.00 - 1.20)	0.01

of SE ( $P = 0.024$ ), altered levels of consciousness (ALOC) ( $P < 0.001$ ), and ANE in cranial imaging ( $P < 0.001$ ). In terms of blood parameter indices, the ICU group presented with lower counts of monocytes ( $P = 0.004$ ) and platelets ( $P = 0.009$ ), but higher levels of PCT ( $P = 0.002$ ), glutamate-pyruvate transaminase (GPT) ( $P < 0.001$ ), lactate dehydrogenase (LDH) ( $P = 0.009$ ), creatine kinase-MB (CK-MB) ( $P = 0.034$ ), D-dimer ( $P = 0.011$ ), as well as interleukin-6 (IL-6) ( $P = 0.022$ ) and interleukin-10 (IL-10) ( $P = 0.004$ ) in peripheral blood (Table 3). In the moderate & severe IAV group, there was also a higher incidence of status epilepticus ( $P = 0.003$ ), ALOC ( $P < 0.001$ ), and ANE ( $P < 0.001$ ), accompanied by elevated levels of CSF protein ( $P = 0.026$ ), peripheral blood leukomonocytes ( $P = 0.033$ ), PCT ( $P = 0.002$ ), GPT ( $P < 0.001$ ), LDH ( $P = 0.004$ ), CK-MB ( $P = 0.005$ ), and the cytokines IL-4 ( $P = 0.037$ ), IL-6 ( $P = 0.022$ ), IL-10 ( $P = 0.004$ ), and tumor necrosis factor-alpha (TNF-α) ( $P = 0.017$ ) (Table 4).

#### 4.3. Comparison of Demographic and Clinical Characteristics Between COVID-19 and Influenza A Virus (IAV) Groups

The median age in the COVID-19 group was 1.45 years (ranging from 0.68 to 2.68), which was younger than that in the IAV group (median 4.30, range from 2.60 to

7.40) ( $P < 0.001$ ). Boys comprised 61.8% of the COVID-19 group, compared to 56.8% in the IAV group, with no significant difference between the two groups ( $P = 0.67$ ). Fever was the initial symptom in all patients in both groups. However, the median time to the onset of neurological symptoms was shorter in the COVID-19 group than in the IAV group (median 0.5 vs. 1.0,  $P < 0.001$ ). In the COVID-19 group, 31 (91.2%) patients experienced seizures, 8 (23.5%) had SE, and 5 (14.7%) exhibited altered levels of consciousness. In comparison, in the IAV group, 32 (86.5%) patients experienced seizures ( $P = 0.71$ ), 13 (35.1%) had SE ( $P = 0.28$ ), and 21 (56.8%) exhibited altered levels of consciousness ( $P < 0.001$ ), indicating that more patients in the IAV group had altered levels of consciousness. When classified by severity, 27 (79.4%) patients in the COVID-19 group were considered mild, 5 (14.7%) were moderate, and 2 (5.9%) were severe cases. In contrast, in the IAV group, 18 (48.6%) were mild, 7 (18.9%) were moderate, and 12 (32.4%) were severe ( $P = 0.01$ ), showing an increase in moderate and severe cases in the IAV group ( $P = 0.007$ ). Consequently, ICU admission was higher in the IAV group, with 22 (59.5%) patients, compared to 6 (17.6%) in the COVID-19 group ( $P < 0.001$ ). Finally, there was 1 (2.9%) death in the COVID-19 group and 7 (18.9%) deaths in the IAV group ( $P = 0.06$ ) (Table 5).

**Table 3.** Comparison of IAV Encephalopathy ICU Group with Non-ICU Group

Influenza A Severity	ICU (n = 22)	Non-ICU (n = 15)	P-Value
Time, day	2.0 (1.0 - 2.2)	1.0 (1.0 - 1.0)	0.019
Status epilepticus <sup>a</sup>	11 (50.0)	2 (13.3)	0.024
ALOC <sup>a</sup>	21 (95.5)	0 (0)	< 0.001
ANE <sup>a</sup>	12 (54.5)	0 (0)	< 0.001
Monocyte, 10 <sup>9</sup> /L	0.28 (0.10 - 0.50)	0.58 (0.35 - 0.86)	0.004
Platelet, 10 <sup>9</sup> /L	159.5 (108.3 - 210.3)	220.0 (177.0 - 304.0)	0.009
PCT, ng/mL	6.35 (0.45 - 24.87)	0.29 (0.11 - 0.59)	0.002
GPT, U/L	70.5 (19.0 - 238.0)	13.0 (11.0 - 23.0)	< 0.001
LDH, U/L	627.0 (276.8 - 1767.0)	305.0 (249.0 - 425.0)	0.009
CK-MB, U/L	55.5 (26.5 - 83.8)	26.0 (16.0 - 53.0)	0.034
D dimer, mg/L	3.35 (1.32 - 44.12)	0.95 (0.34 - 1.33)	0.011
IL-6, pg/mL	30.40 (7.05 - 161.00)	5.80 (2.90 - 19.10)	0.022
IL-10, pg/mL	38.65 (7.80 - 259.65)	4.60 (2.90 - 11.60)	0.004

<sup>a</sup> Values are presented as No. (%).

**Table 4.** Comparison of IVA Encephalopathy Mild Group with Moderate and Severe Group

Influenza A Severity	Mild (n = 18)	Moderate and Severe (n = 19)	P-Value
Status epilepticus <sup>a</sup>	2 (11.1)	11 (57.9)	0.003
ALOC <sup>a</sup>	3 (16.7)	18 (94.7)	< 0.001
ANE <sup>a</sup>	1 (5.5)	11 (57.9)	< 0.001
CSF protein, mg/L	139.0 (89.5 - 326.8)	414.0 (229.4 - 2562.0)	0.026
Leukomonocyte, 10 <sup>9</sup> /L	1.01 (0.66 - 1.92)	1.07 (0.54 - 4.33)	0.033
PCT, ng/mL	0.32 (0.10 - 0.86)	5.87 (0.51 - 35.78)	0.002
GPT U/L	12.5 (11.0 - 21.5)	72.0 (26.0 - 198.0)	< 0.001
LDH, U/L	288.5 (253.5 - 434.8)	681.0 (324.0 - 1869.0)	0.004
CK-MB, U/L	27.0 (16.8 - 49.3)	69.0 (32.0 - 98.0)	0.005
IL-4, pg/mL	1.60 (1.25 - 2.20)	2.10 (1.50 - 2.75)	0.037
IL-6, pg/mL	5.85 (3.05 - 28.65)	21.40 (11.60 - 2583.6)	0.022
IL-10, pg/mL	5.95 (3.35 - 11.80)	47.30 (12.25 - 487.30)	0.004
TNF-α, pg/mL	1.70 (1.00 - 2.15)	2.80 (1.75 - 3.80)	0.017

<sup>a</sup> Values are presented as No. (%).

#### 4.4. A Comparison of Neurological Parameters Between the COVID-19 and Influenza A Virus (IAV) Groups

A comparison of neurological parameters between the COVID-19 and IAV groups revealed that 15 (44.1%) patients in the COVID-19 group and 24 (64.9%) in the IAV

group underwent lumbar puncture. The CSF white cell count (COVID-19 group vs. IAV group, median: 2 vs. 2, P = 0.08), protein levels (median: 227.4 vs. 249.7, P = 0.69), and glucose levels (median: 4.53 vs. 4.14, P = 0.39) showed no significant differences between the two groups. Electroencephalogram monitoring was

**Table 5.** Comparison of COVID-19 Group with IVA Group

Characteristics	COVID-19 (n = 34)	Influenza (n = 37)	P-Value
Age, y	1.45 (0.68 - 2.68)	4.30 (2.60 - 7.40)	< 0.001
Male	21 (61.8)	21 (56.8)	0.67
<b>Symptoms</b>			
Time, day	0.5 (0.5 - 1.0)	1.0 (1.0 - 2.0)	< 0.001
Fever	34 (100)	37 (100)	1.00
Seizure	31 (91.2)	32 (86.5)	0.71
Status epilepticus	8 (23.5)	13 (35.1)	0.28
Altered levels of consciousness	5 (14.7)	21 (56.8)	< 0.001
<b>Severity</b>			
Mild	27 (79.4)	18 (48.6)	
Moderate	5 (14.7)	7 (18.9)	
Severe	2 (5.9)	12 (32.4)	0.007 <sup>a</sup>
ICU admission	6 (17.6)	22 (59.5)	< 0.001
Death	1 (2.9)	7 (18.9)	0.06
<b>CSF<sup>b</sup></b>			
CSF pleocytosis, 10 <sup>6</sup> /L	2 (1 - 3)	2 (2 - 4)	0.08
CSF protein, mg/L	227.4 (201.3 - 403.7)	249.7 (105.5 - 687.0)	0.69
CSF glucose, mmol/L	4.53 (3.56 - 5.07)	4.14 (3.23 - 4.74)	0.47
<b>EEG<sup>b</sup></b>			
Normal	9 (34.6)	8 (40.0)	
Background slow waves	17 (65.4)	12 (60.0)	
Epileptiform activity	0 (0)	0 (0)	
<b>Image<sup>b</sup></b>			
Normal	23 (74.2)	18 (48.6)	0.047 <sup>c</sup>
Encephaledema	2 (6.5)	4 (10.8)	
Haemorrhage evident	0	2 (5.4)	
Hernia	0	3 (8.1)	
MERS	1 (2.7)	2 (5.4)	
ANE	3 (9.7)	12 (32.4)	0.038 <sup>d</sup>

<sup>a</sup> Moderate and severe compared with mild.

<sup>b</sup> Values are presented as No. (%).


<sup>c</sup> Compared with abnormal.

<sup>d</sup> Compared with non-ANE.

performed on 26 (76.5%) patients in the COVID-19 group and 20 (54.1%) in the IAV group. Of these, 17 (65.4%) in the COVID-19 group and 12 (60.0%) in the IAV group exhibited slow waves in the background. No epileptiform activity was observed in either group. Brain MRI was conducted on 29 patients in the COVID-19 group, with 2 also undergoing CT scans, while 30 in the IAV group had brain MRIs, and 7 had CT scans. Normal results were found in 23 (74.2%) patients in the COVID-19 group and 18 (48.6%) in the IAV group, a difference that was statistically significant ( $P = 0.047$ ). Acute necrotizing encephalopathy was present in both groups, more prevalently in the IAV group ( $P = 0.038$ ), as illustrated in [Figure 1](#) and [Table 5](#).

#### 4.5. Comparison of Blood Parameters Between COVID-19 and Influenza A Virus (IAV) Groups

We compared blood parameters between the two groups. The median levels of hemocytes such as white blood cells, red blood cells, and platelets were  $7.68 \times 10^9/L$ ,  $4.24 \times 10^{12}/L$ , and  $219.0 \times 10^9/L$ , respectively, in the COVID-19 group, compared with  $6.19 \times 10^9/L$  ( $P = 0.20$ ),  $4.40 \times 10^{12}/L$  ( $P = 0.21$ ), and  $187.0 \times 10^9/L$  ( $P = 0.18$ ) in the IAV group. The levels of neutrophils and monocytes showed no significant difference between the two groups. Leukomonocytes were significantly lower in the IAV



**Figure 1.** Cranial MRI revealed a high FLAIR signal in the bilateral cerebral hemisphere white matter, basal ganglia, and thalamus, including thalamic swelling in a 1-year-old boy with a COVID-19 infection (A); a high FLAIR signal in the splenium of the corpus callosum in a 3.3-year-old girl with a COVID-19 infection (B); and a high FLAIR signal in the bilateral cerebral hemisphere white matter, basal ganglia, and thalamus in a 4.3-year-old boy with an IAV infection (C); Cranial CT displayed transforaminal magna herniation (D); tentorial herniation (E); extensive cerebral edema, cerebral falx hemorrhage, tentorial hemorrhage, and subarachnoid hemorrhage in a 4.3-year-old boy with an IAV infection (F).

group (COVID-19 group vs. IAV group, median 2.27 vs. 1.06,  $P = 0.003$ ), with a lower proportion of CD4 T cells ( $P = 0.047$ ). Inflammatory indicators such as CRP ( $P = 0.15$ ), PCT ( $P = 0.16$ ), and ESR ( $P = 0.19$ ) showed no significant difference between the two groups. In blood biochemical indices, we compared GPT, LDH, creatine phosphokinase (CK), CK-MB, random blood glucose, and D-dimer between the two groups. Random blood glucose ( $P = 0.001$ ) and D-dimer ( $P = 0.004$ ) levels were lower in the COVID-19 group. In terms of cytokine parameters, IL-4, IL-6, IL-10, TNF- $\alpha$  showed no significant changes between the two groups except for IL-2 and IFN- $\gamma$ . IL-2 levels were lower ( $P = 0.005$ ), and IFN- $\gamma$  levels were

significantly higher in the COVID-19 group ( $P = 0.013$ ) (Table 6).

## 5. Discussion

The reported prevalence of neurological complications in children with COVID-19 ranges from 3.8% to 44% (16-18). These complications include encephalopathy, encephalitis, aseptic meningitis, febrile and nonfebrile seizures, brain abscesses, bacterial meningitis, Reye's syndrome, and cerebral infarction (19, 20). Antoon et al. noted that the most common acute neurological complications of COVID-19 are seizures and encephalopathy (21). Since January 2022, the Omicron

**Table 6.** Comparison of Blood Parameters of the COVID-19 Group with IVA Group

Blood Parameters	COVID - 19 (n = 34)	Influenza (n = 37)	P-Value
White blood cells, 10 <sup>9</sup> /L	7.68 (4.56 - 9.61)	6.19 (3.39 - 8.37)	0.20
Leukomonocyte, 10 <sup>9</sup> /L	2.27 (1.40 - 4.11)	1.06 (0.59 - 2.31)	0.003
CD19, %	28.20 (21.69 - 32.60)	27.85 (21.25 - 34.30)	0.93
CD3, %	61.00 (54.28 - 67.50)	56.98 (52.05 - 67.38)	0.41
CD4, %	35.65 (30.03 - 40.48)	29.60 (22.65 - 36.60)	0.047
CD8, %	19.10 (13.60 - 22.61)	19.60 (16.35 - 25.14)	0.35
CD3 - CD16+CD56+, %	7.45 (4.55 - 11.60)	6.15 (3.91 - 10.98)	0.29
Neutrophils, 10 <sup>9</sup> /L	2.66 (1.61 - 5.16)	4.06 (1.93 - 6.15)	0.18
Monocyte, 10 <sup>9</sup> /L	0.54 (0.39 - 0.85)	0.35 (0.23 - 0.71)	0.05
Red blood cells, 10 <sup>12</sup> /L	4.24 (3.99 - 4.85)	4.40 (4.13 - 4.73)	0.21
Platelet, 10 <sup>9</sup> /L	219.0 (155.0 - 279.0)	187.0 (132.50 - 244.5)	0.18
CRP, mg/L	1.23 (0.58 - 14.56)	5.07 (1.55 - 11.53)	0.15
PCI, ng/mL	0.38 (0.15 - 0.62)	0.86 (0.23 - 10.08)	0.16
ESR, mm/h	4.36 (2.13 - 6.20)	5.51 (2.09 - 10.18)	0.19
GPT, U/L	28.0 (19.8 - 41.3)	23.0 (12.5 - 123.0)	0.59
LDH, U/L	325.0 (277.0 - 487.0)	393.0 (268.0 - 864.0)	0.40
CK, U/L	167.0 (99.0 - 291.5)	155.0 (112.5 - 380.0)	0.68
CK - MB, U/L	31.0 (22.5 - 47.0)	38.0 (21.0 - 73.0)	0.31
Glucose, mmol/L	5.3 (4.9 - 5.9)	6.3 (5.4 - 8.4)	0.001
D dimer, mg/L	0.62 (0.32 - 1.05)	1.6 (0.65 - 12.39)	0.004
IL - 2, pg/mL	1.60 (1.40 - 2.00)	2.20 (1.60 - 2.50)	0.005
IL - 4, pg/mL	1.80 (1.20 - 2.30)	1.80 (1.40 - 2.50)	0.51
IL - 6, pg/mL	23.50 (5.90 - 155.20)	13.80 (3.20 - 118.20)	0.43
IL - 10, pg/mL	10.60 (4.70 - 18.00)	12.40 (4.10 - 69.90)	0.61
TNF - α, pg/mL	1.40 (1.10 - 2.80)	1.90 (1.40 - 3.00)	0.19
IFN - γ, pg/mL	3.80 (2.70 - 5.30)	2.70 (1.70 - 4.20)	0.013

variant has become predominant worldwide (22). Winnie W.Y. Tso et al. reported that the severe outcomes from Omicron are comparable to those from influenza, with children facing the same risk of encephalitis/encephalopathy from the Omicron variant as from the influenza virus (23).

In our study, COVID-19 encephalopathy tended to affect younger children under 2 years of age, presenting earlier with neurological symptoms, whereas IAV-associated encephalopathy affected older children, over 4 years of age. Regarding neurological manifestations, seizures were frequently observed in both groups (7, 12), accompanied by diffuse slowing on EEG recordings. Seizures could be an early indicator of acute SARS-CoV-2 infection, particularly during the spread of the Omicron

variant (24), and were more common in children with COVID-19 infection. However, SE was less common. Altered consciousness was also rare in children with COVID-19 encephalopathy (25), but its presence was associated with the severity of the condition. Conversely, the incidence of ALOC was higher in the IAV group, especially in severe cases. Cranial imaging showed encephal edema, mild encephalitis/encephalopathy with a reversible splenic lesion (MERS), and ANE in both groups, while hemorrhage and herniation occurred only in the IAV group. The incidence of ANE was notably higher in the IAV group, particularly among severe cases. This led to higher ICU admission rates and a higher mortality rate in cases of IAV-associated encephalopathy.

Lymphopenia was primarily observed in critically ill patients with COVID-19 encephalopathy (26), along with a decrease in monocytes (27). In the IAV group, leukomonocytes were significantly lower, even with a decreased expression of CD4+ T cells, though these factors were not associated with the severity of IAV infection. Inflammatory markers such as CRP, ESR, PCT, and IL-6, which were elevated in COVID-19 infections, showed no difference between the two encephalopathy groups (28). Similarly, levels of GPT, LDH, and CK-MB, which are related to the severity of IAV infection (29), also showed no significant difference between the groups, except for D-dimer. D-dimer levels were higher in the IAV group, accompanied by an increased production of LDH, indicating disease severity and poor outcomes (30, 31).

Cytokine storms, described in both COVID-19 and IAV infections, have been associated with high levels of mortality and morbidity (32). These storms were linked to the severity of IAV-associated encephalopathy (33, 34). In cases of SARS-CoV-2 infection with cytokine storms, blood-brain barrier disruption and entry of the virus into the brain could occur (35), with high levels of acute innate inflammatory markers being associated with severe neurological insults (36). In many instances of cytokine storm development, TNF- $\alpha$  and IFN- $\gamma$  levels were elevated. TNF- $\alpha$ , a pro-inflammatory cytokine that contributes to organ damage, has early high levels strongly predicting mortality in COVID-19 (37). In our study, the level of TNF- $\alpha$  was lower in COVID-19 ICU patients and severe cases, suggesting that further research is needed to explore its levels in cerebrospinal fluid. Compared with the IAV group, the COVID-19 group had higher expression of IFN- $\gamma$  (38). As a pro-inflammatory cytokine essential for antiviral defense, IFN- $\gamma$  plays a crucial role in all phases of the immune response (39). Its protective antiviral response in the circulating immune cells of adult COVID-19 patients was strongly associated with lower severity (40). Several studies have demonstrated that IFN- $\gamma$  plays a protective role in various autoimmune disorders, such as autoimmune uveitis and portal inflammation (41, 42). However, persistently high levels of IFN- $\gamma$  can exacerbate systemic inflammation, increasing tissue injury and organ failure. IFN- $\gamma$ -mediated immune responses have been confirmed to cause serious tissue damage during *T. gondii* infection (43, 44). Long known for its pleiotropic effects in various autoimmune disorders, IFN- $\gamma$ 's levels may serve as a clinical indicator for the severity of ANE. Nevertheless, further in-depth research is necessary to support this hypothesis.

The incidence of acute encephalopathy caused by either COVID-19 or IAV was low, indicating that future validation through multicenter and large-scale cohort studies is still necessary. Additionally, since our study was retrospective, we could not obtain certain parameters, such as cytokine levels in the cerebrospinal fluid.

In conclusion, IAV-associated encephalopathy was more prevalent in older children and presented with more severe manifestations, including a higher number of ANE cases. Cytokine storms could be triggered by both COVID-19 and IAV infections. IFN- $\gamma$  may act as a protective cytokine in cases of COVID-19 encephalopathy.

## Footnotes

**Authors' Contribution:** Haifeng Li conceived the study and provided supervision. Jialu Xu and Jiajin Wang collected the samples and conducted the analysis. Wei Li performed the blood and CSF parameters analysis. Jialu Xu prepared the first draft. Wei Li and Yilin Zhu revised the manuscript. All authors approved the manuscript.

**Conflict of Interests:** The authors declare that there are no conflicts of interest.

**Data Availability:** The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Ethical Approval:** The study was approved by the ethics committee of Children's Hospital, Zhejiang University School of Medicine (2019-IRB-091).

**Funding/Support:** This work was supported by a Grant from the Project of Department of Science and Technology of Zhejiang Province (2023C03003) to Haifeng Li.

## References

1. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 Among Children in China. *Pediatr*. 2020;**145**(6). [PubMed ID: 32179660]. <https://doi.org/10.1542/peds.2020-0702>.
2. Liguoro I, Pilotto C, Bonanni M, Ferrari ME, Pusioli A, Nocerino A, et al. SARS-COV-2 infection in children and newborns: a systematic review. *Eur J Pediatr*. 2020;**179**(7):1029-46. [PubMed ID: 32424745]. [PubMed Central ID: PMC7234446]. <https://doi.org/10.1007/s00431-020-03684-7>.
3. Principi N, Esposito S. Are we sure that the neurological impact of COVID 19 in childhood has not been underestimated? *Ital J Pediatr*. 2021;**47**(1):191. [PubMed ID: 34537061]. [PubMed Central ID: PMC8449691]. <https://doi.org/10.1186/s13052-021-01144-y>.
4. Koralnik IJ, Tyler KL. COVID-19: A Global Threat to the Nervous System. *Ann Neurol*. 2020;**88**(1):1-11. [PubMed ID: 32506549]. [PubMed Central ID: PMC7300753]. <https://doi.org/10.1002/ana.25807>.
5. Garg RK, Paliwal VK, Gupta A. Encephalopathy in patients with COVID-19: A review. *J Med Virol*. 2021;**93**(1):206-22. [PubMed ID: 33811111]. <https://doi.org/10.1007/s12250-021-00111-1>.



- 32558956]. <https://doi.org/10.1002/jmv.26207>.
6. Lin JE, Asfour A, Sewell TB, Hooe B, Pryce P, Earley C, et al. Neurological issues in children with COVID-19. *Neurosci Lett*. 2021;743:135567. [PubMed ID: 3352286]. [PubMed Central ID: PMC7831718]. <https://doi.org/10.1016/j.neulet.2020.135567>.
  7. Jantarabenjakul W, Paprad T, Paprad T, Anugulruengkitt S, Pancharoen C, Puthanakit T, et al. Neurological complications associated with influenza in hospitalized children. *Influenza Other Respir Viruses*. 2023;17(1). e13075. [PubMed ID: 36514185]. [PubMed Central ID: PMC9835412]. <https://doi.org/10.1111/irv.13075>.
  8. Togashi T, Matsuzono Y, Narita M, Morishima T. Influenza-associated acute encephalopathy in Japanese children in 1994-2002. *Virus Res*. 2004;103(1-2):75-8. [PubMed ID: 15163492]. <https://doi.org/10.1016/j.virusres.2004.02.016>.
  9. Chi H, Chang L, Chao YC, Lin DS, Yang HW, Fang LC, et al. Pathogenesis and Preventive Tactics of Immune-Mediated Non-Pulmonary COVID-19 in Children and Beyond. *Int J Mol Sci*. 2022;23(22). [PubMed ID: 36430629]. [PubMed Central ID: PMC9696849]. <https://doi.org/10.3390/ijms232214157>.
  10. Hoshino A, Saitoh M, Oka A, Okumura A, Kubota M, Saito Y, et al. Epidemiology of acute encephalopathy in Japan, with emphasis on the association of viruses and syndromes. *Brain Dev*. 2012;34(5):337-43. [PubMed ID: 21924570]. <https://doi.org/10.1016/j.braindev.2011.07.012>.
  11. Ichiyama T, Morishima T, Isumi H, Matsufuji H, Matsubara T, Furukawa S. Analysis of cytokine levels and NF-kappaB activation in peripheral blood mononuclear cells in influenza virus-associated encephalopathy. *Cytokine*. 2004;27(1):31-7. [PubMed ID: 15207249]. <https://doi.org/10.1016/j.cyto.2004.03.012>.
  12. Slooter AJC, Otte WM, Devlin JW, Arora RC, Bleck TP, Claassen J, et al. Updated nomenclature of delirium and acute encephalopathy: statement of ten Societies. *Intensive Care Med*. 2020;46(5):1020-2. [PubMed ID: 32055887]. [PubMed Central ID: PMC7210231]. <https://doi.org/10.1007/s00134-019-05907-4>.
  13. Lim HY, Ho VP, Lim TC, Thomas T, Chan DW. Serial outcomes in acute necrotising encephalopathy of childhood: A medium and long term study. *Brain Dev*. 2016;38(10):928-36. [PubMed ID: 27256511]. <https://doi.org/10.1016/j.braindev.2016.05.002>.
  14. Lowenstein DH, Alldredge BK. Status epilepticus. *N Engl J Med*. 1998;338(14):970-6. [PubMed ID: 9521986]. <https://doi.org/10.1056/NEJM199804023381407>.
  15. Han MS, Kim KM, Oh KJ, Chang JY, Lee SY, Choi JE, et al. Distinct Clinical and Laboratory Features of COVID-19 in Children During the Pre-Delta, Delta and Omicron Wave. *Pediatr Infect Dis J*. 2023;42(5):423-8. [PubMed ID: 36795583]. [PubMed Central ID: PMC10097473]. <https://doi.org/10.1097/INF.0000000000003872>.
  16. Fink EL, Robertson CL, Wainwright MS, Roa JD, Lovett ME, Stulce C, et al. Prevalence and Risk Factors of Neurologic Manifestations in Hospitalized Children Diagnosed with Acute SARS-CoV-2 or MIS-C. *Pediatr Neurol*. 2022;128:33-44. [PubMed ID: 35066369]. [PubMed Central ID: PMC8713420]. <https://doi.org/10.1016/j.pediatrneurol.2021.12.010>.
  17. LaRovere KL, Riggs BJ, Poussaint TY, Young CC, Newhams MM, Maamari M, et al. Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome. *JAMA Neurol*. 2021;78(5):536-47. [PubMed ID: 33666649]. [PubMed Central ID: PMC7936352]. <https://doi.org/10.1001/jamaneurol.2021.0504>.
  18. Ray STJ, Abdel-Mannan O, Sa M, Fuller C, Wood GK, Pysden K, et al. Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study. *Lancet Child Adolesc Health*. 2021;5(9):631-41. [PubMed ID: 34273304]. [PubMed Central ID: PMC8279959]. [https://doi.org/10.1016/S2352-4642\(21\)00193-0](https://doi.org/10.1016/S2352-4642(21)00193-0).
  19. Antoon JW, Hall M, Herndon A, Johnson DP, Brown CM, Browning WL, et al. Prevalence, Risk Factors, and Outcomes of Influenza-Associated Neurologic Complications in Children. *J Pediatr*. 2021;239:32-38 e5. [PubMed ID: 34216629]. [PubMed Central ID: PMC8604779]. <https://doi.org/10.1016/j.jpeds.2021.06.075>.
  20. Antoon JW, Williams DJ, Thurm C, Bendel-Stenzel M, Spaulding AB, Teufel RJ, et al. The COVID-19 Pandemic and Changes in Healthcare Utilization for Pediatric Respiratory and Nonrespiratory Illnesses in the United States. *J Hosp Med*. 2021;16(5):294-7. [PubMed ID: 33734976]. [PubMed Central ID: PMC8086992]. <https://doi.org/10.12788/jhm.3608>.
  21. Antoon JW, Hall M, Howard LM, Herndon A, Freundlich KL, Grijalva CG, et al. COVID-19 and Acute Neurologic Complications in Children. *Pediatr*. 2022;150(5). [PubMed ID: 35949041]. [PubMed Central ID: PMC9633383]. <https://doi.org/10.1542/peds.2022-058167>.
  22. Wolf JM, Wolf LM, Bello GL, Maccari JG, Nasi LA. Molecular evolution of SARS-CoV-2 from December 2019 to August 2022. *J Med Virol*. 2023;95(1). e28366. [PubMed ID: 36458547]. [PubMed Central ID: PMC9877913]. <https://doi.org/10.1002/jmv.28366>.
  23. Tso WWY, Kwan MYW, Wang YL, Leung LK, Leung D, Chua GT, et al. Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections. *Emerg Microbes Infect*. 2022;11(1):1742-50. [PubMed ID: 35730665]. [PubMed Central ID: PMC9258055]. <https://doi.org/10.1080/22221751.2022.2093135>.
  24. Bova SM, Serafini L, Serati I, Fiori L, Veggiotti P. Seizures may be an early sign of acute COVID-19, and the Omicron variant could present a more epileptogenic profile. *Acta Paediatr*. 2022;111(9):1814-5. [PubMed ID: 35615863]. [PubMed Central ID: PMC9348245]. <https://doi.org/10.1111/apa.16424>.
  25. Cho SM, White N, Premraj L, Battaglini D, Fanning J, Suen J, et al. Neurological manifestations of COVID-19 in adults and children. *Brain*. 2023;146(4):1648-61.
  26. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506. [PubMed ID: 31986264]. [PubMed Central ID: PMC7159299]. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
  27. Xiong X, Chua GT, Chi S, Kwan MYW, Wong WHS, Zhou A, et al. Haematological and immunological data of Chinese children infected with coronavirus disease 2019. *Data Brief*. 2020;31:105953. [PubMed ID: 32685628]. [PubMed Central ID: PMC7324312]. <https://doi.org/10.1016/j.dib.2020.105953>.
  28. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507-13. [PubMed ID: 32007143]. [PubMed Central ID: PMC7135076]. [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7).
  29. Lu Z, Zheng Y, He Y, Chen H, Wang H, Cao L, et al. Pandemic 2009 influenza A (H1N1)-associated deaths among children in China: A retrospective analysis. *Pediatr Investig*. 2018;2(3):166-71. [PubMed ID: 32851255]. [PubMed Central ID: PMC7331416]. <https://doi.org/10.1002/ped4.12053>.
  30. Kanchana S, Kanchana S, Vijitsopa T, Thammakumpee K, Yamwong S, Sawanyawisuth K. Clinical factors predictive of pneumonia caused by pandemic 2009 H1N1 influenza virus. *Am J Trop Med Hyg*. 2013;88(3):461-3. [PubMed ID: 23382162]. [PubMed Central ID: PMC3592525]. <https://doi.org/10.4269/ajtmh.12-0132>.
  31. Wang ZF, Su F, Lin XJ, Dai B, Kong LF, Zhao HW, et al. Serum D-dimer changes and prognostic implication in 2009 novel influenza A(H1N1). *Thromb Res*. 2011;127(3):198-201. [PubMed ID: 21216444]. <https://doi.org/10.1016/j.thromres.2010.11.032>.
  32. Morris G, Bortolasci CC, Puri BK, Marx W, O'Neil A, Athan E, et al. The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared.

- Can one sized treatment fit all? *Cytokine*. 2021;**144**:155593. [PubMed ID: 34074585]. [PubMed Central ID: PMC8149193]. <https://doi.org/10.1016/j.cyto.2021.155593>.
33. Sun G, Ota C, Kitaoka S, Chiba Y, Takayanagi M, Kitamura T, et al. Elevated serum levels of neutrophil elastase in patients with influenza virus-associated encephalopathy. *J Neurol Sci*. 2015;**349**(1-2):190-5. [PubMed ID: 25626769]. <https://doi.org/10.1016/j.jns.2015.01.017>.
  34. Morichi S, Yamanaka G, Ishida Y, Oana S, Kashiwagi Y, Kawashima H. Brain-derived neurotrophic factor and interleukin-6 levels in the serum and cerebrospinal fluid of children with viral infection-induced encephalopathy. *Neurochem Res*. 2014;**39**(11):2143-9. [PubMed ID: 25119165]. <https://doi.org/10.1007/s11064-014-1409-9>.
  35. Kempuraj D, Selvakumar GP, Ahmed ME, Raikwar SP, Thangavel R, Khan A, et al. COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation. *Neuroscientist*. 2020;**26**(5-6):402-14. [PubMed ID: 32684080]. <https://doi.org/10.1177/1073858420941476>.
  36. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic Features in Severe SARS-CoV-2 Infection. *N Engl J Med*. 2020;**382**(23):2268-70. [PubMed ID: 32294339]. [PubMed Central ID: PMC7179967]. <https://doi.org/10.1056/NEJMc2008597>.
  37. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med*. 2020;**26**(10):1636-43. [PubMed ID: 32839624]. [PubMed Central ID: PMC7869028]. <https://doi.org/10.1038/s41591-020-1051-9>.
  38. Alahdal M, Elkord E. Exhaustion and over-activation of immune cells in COVID-19: Challenges and therapeutic opportunities. *Clin Immunol*. 2022;**245**:109177. [PubMed ID: 36356848]. [PubMed Central ID: PMC9640209]. <https://doi.org/10.1016/j.clim.2022.109177>.
  39. Robinson CM, O'Dee D, Hamilton T, Nau GJ. Cytokines involved in interferon-gamma production by human macrophages. *J Innate Immun*. 2010;**2**(1):56-65. [PubMed ID: 20375623]. [PubMed Central ID: PMC2943519]. <https://doi.org/10.1159/000247156>.
  40. Galbraith MD, Kinning KT, Sullivan KD, Araya P, Smith KP, Granrath RE, et al. Specialized interferon action in COVID-19. *Proc Natl Acad Sci USA*. 2022;**119**(11). [PubMed ID: 35217532]. [PubMed Central ID: PMC8931386]. <https://doi.org/10.1073/pnas.2116730119>.
  41. Zhao Y, Wang J, Min Z, Peng L, Qi S, Lin W. I-a(low)CD11b(high) DC Regulates the Immune Response in the Eyes of Experimental Autoimmune Uveitis. *Mediators Inflamm*. 2020;**2020**:6947482. [PubMed ID: 32256194]. [PubMed Central ID: PMC7085850]. <https://doi.org/10.1155/2020/6947482>.
  42. Syu BJ, Loh CE, Hsueh YH, Gershwin ME, Chuang YH. Dual Roles of IFN-gamma and IL-4 in the Natural History of Murine Autoimmune Cholangitis: IL-30 and Implications for Precision Medicine. *Sci Rep*. 2016;**6**:34884. [PubMed ID: 27721424]. [PubMed Central ID: PMC5056512]. <https://doi.org/10.1038/srep34884>.
  43. Gazzinelli RT, Wysocka M, Hieny S, Schariton-Kersten T, Cheever A, Kuhn R, et al. In the absence of endogenous IL-10, mice acutely infected with *Toxoplasma gondii* succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. *J Immunol*. 1996;**157**(2):798-805. [PubMed ID: 8752931].
  44. Liesenfeld O, Kosek J, Remington JS, Suzuki Y. Association of CD4+ T cell-dependent, interferon-gamma-mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with *Toxoplasma gondii*. *J Exp Med*. 1996;**184**(2):597-607. [PubMed ID: 8760813]. [PubMed Central ID: PMC2192709]. <https://doi.org/10.1084/jem.184.2.597>.